.

Pharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 6,753,013

« Back to Dashboard

Which drugs does patent 6,753,013 protect, and when does it expire?

Patent 6,753,013 protects TACLONEX and ENSTILAR and is included in three NDAs. There has been one Paragraph IV challenge on Taclonex.

This patent has forty-two patent family members in twenty-seven countries.

Summary for Patent: 6,753,013

Title: Pharmaceutical composition
Abstract:A pharmaceutical composition for dermal use, wherein the composition has a first pharmacologically active component A consisting of at least one vitamin D or vitamin D analogue, and a second pharmacologically active component B consisting of at least one corticosteroid, wherein the difference between the maximum stability pH of said first component A and the maximum stability pH of said second component B is at least 1. The composition can also have at least one solvent component C, where component C is compounds of the general formula R.sup.3 (OCH.sub.2 C(R.sup.1)H).sub.x OR.sup.2 (I), wherein x is in the range of 2-60, R.sup.1 in each of the x units independently is H or CH.sub.3, R.sup.2 is straight chain or branched C.sub.1-20 alkyl or benzoyl, and R.sup.3 is H or phenylcarbonyloxy; di-(straight or branched)-C.sub.4-10 alkyl esters of C.sub.4 -C.sub.8 dicarboxylic acids; straight or branched C.sub.12-18 -alkyl benzoates; straight or branched C.sub.2-4 -alkyl esters of straight or branched C.sub.10-18 -alkanoic or -alkenoic acids; propylenglycol diesters with C.sub.8-14 -alkanoic acids; and branched primary C.sub.18-24 alkanols.
Inventor(s): Didriksen; Erik (Ballerup, DK), H.o slashed.y; Gert (Ballerup, DK)
Assignee: Leo Pharmaceutical Products, Ltd. A/S (Ballerup, DK)
Application Number:09/959,367
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006RXYesYes6,753,013► SubscribeY TREATMENT OF MODERATE PLAQUE PSORIASIS
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
OINTMENT;TOPICAL021852-001Jan 9, 2006RXYesYes6,753,013► SubscribeY PSORIASIS
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes6,753,013► SubscribeY PSORIASIS
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes6,753,013► SubscribeY PLAQUE PSORIASIS
Leo Pharma As
TACLONEX
betamethasone dipropionate; calcipotriene hydrate
SUSPENSION;TOPICAL022185-001May 9, 2008RXYesYes6,753,013► SubscribeY TREATMENT OF MODERATE PLAQUE PSORIASIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,753,013

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark1999 00561Apr 23, 1999
PCT Information
PCT FiledJanuary 27, 2000PCT Application Number:PCT/DK00/00033
PCT Publication Date:November 02, 2000PCT Publication Number: WO00/64450

International Patent Family for Patent: 6,753,013

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal2455083► Subscribe
Portugal1178808► Subscribe
Poland199123► Subscribe
Poland351387► Subscribe
New Zealand515142► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc